Quantitative and qualitative assessment of milk production after pharmaceutical induction of lactation in the mare.
The induction of lactation is performed in ruminants by steroidogenic impregnation, followed by drugs intended to increase prolactin secretion. The aim of this study was to induce lactation in barren mares and to evaluate milk production. Five treated and 5 control mares were used in June and September in year 1, and 12 mares were used in year 2. Mares were administered a vaginal pessary (500 mg altrenogest and 50 mg estradiol benzoate) for 1 week. The 2nd week, another sponge with 100 mg estradiol benzoate was administered, together with 50 mg/100 kg body weight (BW) sulpiride in oil (IM q12h). All mares were milked by hand. Drug treatment was stopped after I L was obtained. Milk production and composition and plasma prolactin concentration were measured. In year 2, the same steroid treatment was applied, but mares received sulpiride (n = 6) or domperidone (1.1 mg/kg PO q12h) (n = 6). A milking machine and oxytocin injections 1 minute before the start of milking were used. In year 1, all treated mares started milking within 1-5 days after sulpiride treatment. Mean daily milk production was 0.88 +/- 0.52 L/500 kg BW. Milk immunoglobulin G (IgG) contents increased in all mares (IgG concentration range, 14-92 g/L). Plasma prolactin increased during sulpiride treatment (range. 27.7 +/- 2.9 to 43.7 +/- 6.7 ng/mL [before] to 289.0 +/- 7.8 ng/mL during treatment, P < .001). In year 2, results were similar to those in year 1, with peak IgG concentrations ranging from 4.2 to 106.7 g/L and a larger daily milk production (3.13 +/- 0.75 with sulpiride and 3.45 +/- 0.51 L/500 kg BW with domperidone). In conclusion, lactation can be induced in mares within 2 weeks, and some mares produce good-quality colostrum.
Chavatte-Palmer
P
P
UMR INRA/ENVA 1190, Biologie du Développement et Biotechnologies, Jouy en Josas, France. chavatte@jouy.inra.fr
Arnaud
G
G
Duvaux-Ponter
C
C
Brosse
L
L
Bougel
S
S
Daels
P
P
Guillaume
D
D
Clément
F
F
Palmer
E
E
D000282:Administration, Intravaginal; D000818:Animals; D001947:Breeding; D004294:Domperidone / Q000008:administration & dosage*; D018492:Dopamine Antagonists / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006736:Horses / Q000502:physiology*; D007074:Immunoglobulin G / Q000378:metabolism; D007247:Infertility, Female / Q000662:veterinary; D007774:Lactation / Q000187:drug effects / Q000502:physiology*; D008892:Milk / Q000737:chemistry / Q000502:physiology*; D011388:Prolactin / Q000097:blood; D013469:Sulpiride / Q000008:administration & dosage*; D014204:Trenbolone Acetate / Q000008:administration & dosage / Q000031:analogs & derivatives*
D018492:Dopamine Antagonists; D007074:Immunoglobulin G; C074283:estradiol 3-benzoate; C023445:altrenogest; D004958:Estradiol; D004294:Domperidone; D013469:Sulpiride; D011388:Prolactin; D014204:Trenbolone Acetate